The recent emergence of a new variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) called Omicron (B.1.1.529) has raised paramount concerns in scientific and medical communities due to the presence of several mutations in the spike protein, many of which are located within the receptor binding domain (RBD).1 Some of these mutations were found to have a substantial influence on host cells receptor and anti-SARS-CoV-2 antibodies binding,2 which may then impact infectivity and neutralizing antibodies escape, thus potentially magnifying the risk of COVID-19 (coronavirus disease 2019) vaccine breakthrough. We have hence carried out a scientific literature search, aimed at summarizing the currently published evidence on Omicron variant neutralizing properties of serum or plasma collected from recipients of COVID-19 vaccines.
Neutralizing potency of COVID‐19 vaccines against the SARS‐CoV‐2 Omicron (B.1.1.529) variant
Lippi, Giuseppe
;Mattiuzzi, Camilla;
2022-01-01
Abstract
The recent emergence of a new variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) called Omicron (B.1.1.529) has raised paramount concerns in scientific and medical communities due to the presence of several mutations in the spike protein, many of which are located within the receptor binding domain (RBD).1 Some of these mutations were found to have a substantial influence on host cells receptor and anti-SARS-CoV-2 antibodies binding,2 which may then impact infectivity and neutralizing antibodies escape, thus potentially magnifying the risk of COVID-19 (coronavirus disease 2019) vaccine breakthrough. We have hence carried out a scientific literature search, aimed at summarizing the currently published evidence on Omicron variant neutralizing properties of serum or plasma collected from recipients of COVID-19 vaccines.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
